

September 6, 2019

## U.S. Court Dismisses Novartis Patent Infringement Suit Against Regeneron

[Regeneron Pharmaceuticals, Inc.](#) (NASDAQ: **REGN**), announced that on September 5, 2019, the U.S. District Court for the Southern District of New York ruled in the company's favor, dismissing the patent infringement suit relating to U.S. Patent No. 5,688,688 (the "688 Patent") filed by Novartis Vaccines and Diagnostics, Inc., Novartis Pharma AG, and Grifols Worldwide Operations Limited (collectively, Novartis) in 2018. The District Court entered a judgement of non-infringement and dismissed with prejudice all of Novartis' claims. This means that the manufacture, sale and marketing of EYLEA® (aflibercept) Injection and ZALTRAP® (ziv-aflibercept) do not infringe the claims of the '688 Patent.

Regeneron is pleased with the U.S. District Court decision, and will continue to vigorously defend against any meritless claims of patent infringement.

### **Forward-Looking Statements and Use of Digital Media**

*This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the ultimate outcome of any such proceedings and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the quarterly period ended June 30, 2019. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.*

*Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (<http://newsroom.regeneron.com>) and its Twitter feed (<http://twitter.com/regeneron>).*

**Contacts:****Media Relations**

Sarah Cornhill

Tel: +1 (914) 847-5018

[Sarah.Cornhill@regeneron.com](mailto:Sarah.Cornhill@regeneron.com)

**Investor Relations**

Justin Holko

Tel: +1 (914) 847-7786

[Justin.Holko@regeneron.com](mailto:Justin.Holko@regeneron.com)